These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18677020)

  • 1. Universal screening for methicillin-resistant Staphylococcus aureus by hospitals.
    Harris R
    JAMA; 2008 Aug; 300(5):503; author reply 504-5. PubMed ID: 18677020
    [No Abstract]   [Full Text] [Related]  

  • 2. Universal screening for methicillin-resistant Staphylococcus aureus by hospitals.
    Salgado CD; Vos MC; Farr BM
    JAMA; 2008 Aug; 300(5):503-4; author reply 504-5. PubMed ID: 18677019
    [No Abstract]   [Full Text] [Related]  

  • 3. Universal screening for methicillin-resistant Staphylococcus aureus by hospitals.
    Jarvis WR; Muto C
    JAMA; 2008 Aug; 300(5):504; author reply 504-6. PubMed ID: 18677021
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence and risk factors for MRSA in adult emergency admissions: a case for screening all patients?
    Guleri A; Sharma R; Smith GW
    J Hosp Infect; 2007 Sep; 67(1):96-7. PubMed ID: 17719680
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective?
    Papia G; Louie M; Tralla A; Johnson C; Collins V; Simor AE
    Infect Control Hosp Epidemiol; 1999 Jul; 20(7):473-7. PubMed ID: 10432159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing MRSA infections: finding it is not enough.
    Diekema DJ; Climo M
    JAMA; 2008 Mar; 299(10):1190-2. PubMed ID: 18334697
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical effectiveness and cost benefit of universal versus targeted methicillin-resistant Staphylococcus aureus screening upon admission in hospitals.
    Leonhardt KK; Yakusheva O; Phelan D; Reeths A; Hosterman T; Bonin D; Costello M
    Infect Control Hosp Epidemiol; 2011 Aug; 32(8):797-803. PubMed ID: 21768764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare-acquired infections. The pound sterling 1bn bug.
    Cowper A
    Health Serv J; 2004 Oct; 114(5926):41-5. PubMed ID: 15523995
    [No Abstract]   [Full Text] [Related]  

  • 9. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control.
    Gould IM
    Int J Antimicrob Agents; 2006 Nov; 28(5):379-84. PubMed ID: 17045462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection.
    Gavaldà L; Masuet C; Beltran J; Garcia M; Garcia D; Sirvent JM; Ramon JM
    Infect Control Hosp Epidemiol; 2006 Nov; 27(11):1264-6. PubMed ID: 17080390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients.
    Harbarth S; Fankhauser C; Schrenzel J; Christenson J; Gervaz P; Bandiera-Clerc C; Renzi G; Vernaz N; Sax H; Pittet D
    JAMA; 2008 Mar; 299(10):1149-57. PubMed ID: 18334690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for methicillin-resistant Staphylococcus aureus in the endemic hospital: what have we learned?
    Rubinovitch B; Pittet D
    J Hosp Infect; 2001 Jan; 47(1):9-18. PubMed ID: 11161895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A flexible approach to methicillin-resistant Staphylococcus aureus (MRSA).
    Nolan JL
    Nurs Times; 2001 Nov 15-21; 97(46):57-8. PubMed ID: 11966057
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment.
    Wernitz MH; Keck S; Swidsinski S; Schulz S; Veit SK
    Clin Microbiol Infect; 2005 Jun; 11(6):466-71. PubMed ID: 15882196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Search and destroy policy for methicillin-resistant Staphylococcus aureus: cost-benefit analysis.
    Simoens S; Ophals E; Schuermans A
    J Adv Nurs; 2009 Sep; 65(9):1853-9. PubMed ID: 19694848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of endemic MRSA.
    Bowler IC; Storr JA
    J Hosp Infect; 1998 Oct; 40(2):159. PubMed ID: 9819696
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cost/benefit calculations of meticillin-resistant Staphylococcus aureus screening methods and their practical importance].
    Knausz M; Kaproncai G; Rozgonyi F
    Orv Hetil; 2010 May; 151(22):893-8. PubMed ID: 20478810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why we disagree with the analysis of Wenzel et al.
    Farr BM; Jarvis WR
    Infect Control Hosp Epidemiol; 2009 May; 30(5):497-9; author reply 499-500. PubMed ID: 19344270
    [No Abstract]   [Full Text] [Related]  

  • 19. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit.
    Chaix C; Durand-Zaleski I; Alberti C; Brun-Buisson C
    JAMA; 1999 Nov; 282(18):1745-51. PubMed ID: 10568647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for methicillin-resistant Staphylococcus aureus.
    McCaughey B
    Infect Control Hosp Epidemiol; 2009 Sep; 30(9):927-8. PubMed ID: 19653825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.